Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Wu et al., EV-DNA vs ctDNA meta-analysis (PMID 41988016)
🔴 Early cancer detection | Systematic review & meta-analysis | n=765
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First meta-analysis directly comparing EV-DNA and ctDNA head-to-head across tumor types; EV-DNA as a complementary biomarker class is modestly novel but builds on established liquid biopsy literature |
| Clinical Relevance | 7 | Directly informs liquid biopsy test selection and multi-analyte panel design; supports clinical adoption decisions |
| Population Reach | 8 | Broad cross-cancer applicability; liquid biopsy is relevant to nearly all solid tumor oncology |
| Implementation Speed | 6 | Technology exists in practice; meta-analysis provides the evidence base needed for protocol integration, but heterogeneous platforms remain a barrier |
| Evidence Strength | 8 | Systematic review + meta-analysis with Bayesian credible intervals; 12 studies, 765 patients; PMC full text reviewed; robust methodology |
Key quantitative result: EV-DNA sensitivity 64.6% (95% CrI 48.8–79.4%), specificity 93.3% (95% CrI 86.8–96.9%); ctDNA sensitivity 70.0%, specificity 90.6%. Small performance differential with complementary profiles.
External validation: The meta-analysis itself pools 12 independent studies — provides cross-study validation. No independent replication of the meta-analysis yet.
Main limitation: Only 12 studies (n=765) with likely heterogeneous assay platforms, tumor types, and mutation targets; small total N limits subgroup precision.
Equity implications: Liquid biopsy access remains concentrated in high-income settings and tertiary centers; broader adoption could benefit underscreened populations if costs decrease, but current infrastructure favors well-resourced health systems.
Evidence Maturity: Validated ✓ (confirmed)
Article 2 — Janiak et al., Platelets as ovarian cancer biomarker (PMID 41991387)
🔴 Early cancer detection | Narrative review | Ovarian cancer
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Platelet-based liquid biopsy for ovarian cancer is genuinely novel as a synthesized framework; concept of "educated platelets" is emerging but not yet mainstream |
| Clinical Relevance | 5 | High unmet need (ovarian cancer late-stage detection is a major cause of mortality), but this is a narrative review — no direct clinical data presented |
| Population Reach | 5 | Ovarian cancer affects ~300,000 women/year globally; significant unmet need amplifies relative reach |
| Implementation Speed | 3 | Exploratory; no clinical validation studies in review; 5–10+ years to clinical utility |
| Evidence Strength | 3 | Narrative review, abstract only, medium classification confidence; no primary data |
Key quantitative result: None reported (narrative synthesis only).
External validation: Not applicable — review article.
Main limitation: Narrative review design; no primary data; abstract-only access; medium classification confidence.
Equity implications: Ovarian cancer disproportionately diagnosed late, often in under-resourced settings lacking CA-125 follow-up infrastructure. A blood-based platelet biomarker could democratize early detection if validated, but technology development likely to concentrate in high-income settings first.
Evidence Maturity: Revised to Exploratory (confirmed from triage)
Article 3 — Shoucair et al., ctDNA in HCC liver transplantation (PMID 41990988)
🔴 Early cancer detection | Targeted literature review | HCC/liver transplant
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA for HCC recurrence detection is an established concept; the novel contribution is the implementation barrier analysis and roadmap for transplant settings specifically |
| Clinical Relevance | 7 | The 3–8 month lead time on recurrence detection vs imaging is clinically actionable; transplant surveillance is a high-stakes setting with limited current tools |
| Population Reach | 4 | HCC + liver transplant is a focused subspecialty population; globally ~900,000 HCC cases/year, but transplant-eligible subgroup is much smaller |
| Implementation Speed | 4 | Platform heterogeneity, 7–14 day turnaround, and lack of reimbursement are identified barriers; mid-term timeline (3–5 years for standardization) |
| Evidence Strength | 5 | Targeted literature review, abstract only; synthesis of existing evidence rather than primary data; high classification confidence partially offsets design limitations |
Key quantitative result: ctDNA detects recurrence 3–8 months before radiographic progression in post-transplant HCC.
External validation: Review synthesizes multiple studies; no independent validation of conclusions.
Main limitation: Targeted (not systematic) review; abstract only; no primary data; implementation barriers documented but not quantified.
Equity implications: Liver transplantation access is itself highly inequitable globally. Even within transplant centers, ctDNA monitoring will initially be available only at well-resourced academic programs.
Evidence Maturity: Validated ✓ (confirmed — underlying evidence base is validated, though review methodology is limited)
Article 4 — Lin et al., Spatial multi-omics of GBM (PMID 41992007)
⚪ Promising but preliminary | Multi-modal spatial transcriptomics | n=100 GBM
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Largest-scale spatial multi-omics atlas of GBM to date; 121 spatial profiles from 100 patients; integration of 4 orthogonal modalities including patch-seq; identifies four spatially organized malignant communities — genuinely groundbreaking atlas work |
| Clinical Relevance | 5 | Preclinical/translational; no immediate clinical intervention, but identifies MES-Hyp/MES-Ast therapeutic targets with mechanistic depth that will directly shape next-generation GBM trial design |
| Population Reach | 5 | GBM ~10,000 new U.S. cases/year; rare but uniformly fatal; high unmet need amplifies score relative to raw case count |
| Implementation Speed | 2 | Basic/translational discovery; therapeutic targets require drug development, preclinical validation, and clinical trials — 10+ year horizon |
| Evidence Strength | 7 | Nature Neuroscience, large n=100 human cohort, multi-modal orthogonal validation; abstract only limits full assessment, but study design is exceptionally rigorous |
Key quantitative result: 121 spatial transcriptomics profiles; four distinct malignant communities with consistent cell-type compositions; synaptic connections predominantly between neurons and OPC-like tumor cells.
External validation: Not yet externally replicated; internal cross-modal validation across 4 omics platforms provides strong internal consistency.
Main limitation: Abstract only; no direct therapeutic intervention data; translation from molecular map to druggable target is a major leap; population is likely skewed to surgical candidates.
Equity implications: GBM surgery and advanced genomic profiling are concentrated in major academic centers; spatial transcriptomics is not a routine clinical tool. Benefits will initially accrue to patients with access to tertiary neuro-oncology programs.
Evidence Maturity: Revised to Exploratory (confirmed — landmark atlas but no clinical translation yet)
Article 5 — Alcala-Millan et al., AI vs GPs for diabetic retinopathy screening (PMID 41991402)
🟢 Near-term implementable | Cross-sectional validation | n=500 T2DM
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI for DR screening is an established concept; this study adds head-to-head GP comparison in primary care with a commercial system (EyeArt v3.0.0) and 100% moderate-to-severe DR capture |
| Clinical Relevance | 8 | T2DM DR screening is a high-volume, guideline-mandated activity; AI clearly outperforming GPs with near-ophthalmologist-level accuracy has direct workflow implications |
| Population Reach | 9 | >500 million people with T2DM globally; DR is a leading cause of preventable blindness; this affects a massive, undertreated population |
| Implementation Speed | 7 | Commercial AI system already exists (EyeArt); primary care deployment infrastructure is feasible; main barriers are reimbursement, training, and multicentre validation |
| Evidence Strength | 6 | Cross-sectional, single-center, n=500; strong performance metrics (κ=0.91, 98.2% sensitivity) but abstract only, no cost-effectiveness data, and no multicentre validation yet |
Key quantitative result: AI κ=0.91 vs ophthalmology; sensitivity 98.2%, specificity 98.9%; GP κ=0.84, sensitivity 86.4%; AI detected 100% of moderate-to-severe DR.
External validation: Single-center; prior EyeArt studies exist but this is a new primary care GP-comparison design. Multicentre replication explicitly recommended.
Main limitation: Single center, single commercial system, abstract only; does not address cost-effectiveness or real-world workflow integration; no longitudinal outcomes.
Equity implications: DR blindness disproportionately affects lower-income populations with poor ophthalmology access; AI-enabled primary care screening could significantly reduce this disparity if deployed equitably. Current deployment in Spain (11% DR prevalence) may not generalize to higher-prevalence, lower-resource settings.
Evidence Maturity: Validated ✓ (confirmed)
Article 6 — Wang et al., IRF4-PAICS-LDHA axis in DLBCL (PMID 41991742)
⚪ Promising but preliminary | Single-cell transcriptomics + ML + animal model | DLBCL
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | ML-identified multi-targetable metabolic-immune axis (IRF4→PAICS→LDHA) is a novel mechanistic pathway in DLBCL; PAICS as an immunosuppressive node is not widely characterized |
| Clinical Relevance | 4 | Mixed species (human + mouse xenograft); preclinical functional validation; methotrexate repurposing angle is clinically interesting but requires trial-level evidence; cannot exceed 5 for non-human studies |
| Population Reach | 5 | DLBCL is the most common aggressive lymphoma (~25,000 US cases/year); significant unmet need in relapsed/refractory setting |
| Implementation Speed | 2 | Basic/translational; animal-model validation only; 5–10+ year horizon to clinical utility |
| Evidence Strength | 5 | Integrative multi-modal design is rigorous; but abstract only, mixed species, no human clinical outcomes, no independent replication |
Key quantitative result: PAICS identified as central immunosuppressive node via 33-gene ML panel; methotrexate and LDHA knockdown reverse T cell exhaustion in functional assays.
External validation: Not externally replicated; functional assays provide internal validation.
Main limitation: Preclinical/mixed species; abstract only; translation from xenograft to human DLBCL is uncertain; methotrexate is not currently used in DLBCL and introducing it would require trial design.
Equity implications: DLBCL R/R patients with limited treatment options could benefit; DLBCL care is concentrated in academic centers globally.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 7 — Zhuo et al., NK cells and JAB1 in NPC (PMID 41992060)
⚪ Promising but preliminary | RNA-seq + scRNA-seq + humanized mouse | NPC
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | JAB1 as a regulator of NK cytotoxicity in NPC is novel; CD16+CD57+ NK subset as a prognostic biomarker is not well established; dual biomarker/target discovery in a single study |
| Clinical Relevance | 4 | Mixed species; preclinical; biomarker outperforming SCC/CEA is interesting but requires prospective clinical validation; capped at 5 |
| Population Reach | 4 | NPC is regionally endemic (Southeast Asia, North Africa); ~130,000 new cases/year globally; not a rare disease but geographically concentrated |
| Implementation Speed | 2 | Preclinical; humanized mouse model; no clinical biomarker validation; 5–10+ year horizon |
| Evidence Strength | 5 | Multi-modal design with functional validation; humanized mouse model adds translational layer; but abstract only, mixed species, no prospective cohort data |
Key quantitative result: CD16+CD57+ NK cells correlate with better prognosis; JAB1/CD107a superior to SCC/CEA as diagnostic/prognostic biomarkers (no specific metrics reported in abstract).
External validation: Not externally validated.
Main limitation: Abstract only; mixed species; no head-to-head quantitative biomarker comparison metrics in available data; regional disease limiting global generalizability.
Equity implications: NPC is most common in Southeast Asia and North Africa — populations with limited access to advanced immunotherapy. Novel biomarkers and targets developed in high-income research settings may not reach highest-burden populations quickly.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 8 — Moreno et al., OTC in pediatric oncology (PMID 41991899)
🟡 Underserved/high-risk population | Retrospective observational | n=159, 15 years
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Ovarian tissue cryopreservation in pediatric oncology is an established practice; 15-year single-center experience adds important outcome data but does not introduce new concepts |
| Clinical Relevance | 7 | POI in 43% of evaluable patients is a high-impact finding; provides a structured care model template; directly relevant to leukemia/lymphoma HSCT programs |
| Population Reach | 5 | Pediatric oncology patients facing gonadotoxic therapy; significant subset of childhood cancer survivors; amplified by lifelong reproductive and endocrine consequences |
| Implementation Speed | 6 | OTC is an established procedure; the care coordination model is implementable in existing pediatric oncology programs; barriers are logistical and financial |
| Evidence Strength | 5 | Retrospective single-center, abstract only; 15-year longitudinal design and n=159 provide reasonable depth, but single-center limits generalizability |
Key quantitative result: POI diagnosed in 43.4% of evaluable patients; concurrent anesthesia coordination achieved in 66.6%.
External validation: Single-center; no comparator arm or external replication.
Main limitation: Retrospective, single-center, abstract only; "evaluable" denominator for POI outcomes not specified in abstract; no reproductive outcome data (live birth rates).
Equity implications: Fertility preservation is dramatically underutilized in low- and middle-income countries; even in Spain (a high-income country), this program is a specialized referral center. Globally, most girls with cancer lack access to OTC entirely.
Evidence Maturity: Validated ✓ (confirmed — within its retrospective design)
Article 9 — Soler-Espejo et al., Seasonal temperature and AF outcomes (PMID 41990305)
🟢 Near-term implementable | Prospective comparative cohort | n=13,629
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Seasonal-cardiovascular associations are known; the novel element is the climate-zone comparison (heat-adapted vs temperate) showing a paradoxical stroke risk increase with extreme heat in heat-adapted populations |
| Clinical Relevance | 6 | Actionable for patient counseling and AF management protocol adjustment during seasonal extremes; 3.6-fold stroke risk increase is a clinically meaningful signal |
| Population Reach | 8 | AF affects ~60 million people globally; increasingly relevant as climate change increases frequency of extreme heat events |
| Implementation Speed | 7 | No new technology required; findings translate directly to patient education, seasonal anticoagulation monitoring adjustments, and public health advisories |
| Evidence Strength | 6 | Large n=13,629 prospective cohort with 2-year follow-up; multi-site; abstract only limits full assessment of confounders and analytical methods |
Key quantitative result: Extreme summer heat increases ischemic stroke risk 3.6-fold vs temperate city; summer associated with lower MACE/cardiovascular death in heat-adapted (Murcia) population.
External validation: Two-city comparative design provides internal cross-validation; no independent external replication.
Main limitation: Abstract only; two Spanish cities — generalizability to other climate zones and ethnicities uncertain; confounders (medication adherence, activity patterns) not assessable from abstract.
Equity implications: Elderly AF patients in low-income settings with limited air conditioning access face highest summer heat risks; climate-AF interaction disproportionately affects lower-income and older populations globally.
Evidence Maturity: Validated ✓ (confirmed within cohort design)
Article 10 — Ono et al., Tirzepatide in hypertensive rats (PMID 41992025)
⚪ Promising but preliminary | Animal experiment | Stroke-prone SHR rats
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Paradoxical BP elevation and cardiac hypertrophy with tirzepatide in non-obese hypertensive model is counter to prevailing clinical narrative; POMC pathway mechanism is a novel hypothesis |
| Clinical Relevance | 3 | Animal only; cannot exceed 5; finding is hypothesis-generating for a clinically important safety question, but no human data |
| Population Reach | 5 | Tirzepatide is prescribed to millions; the non-obese hypertensive subgroup receiving tirzepatide is potentially substantial |
| Implementation Speed | 2 | Animal model only; clinical observational studies or re-analysis of existing trial data would be needed before any practice change |
| Evidence Strength | 4 | Controlled animal experiment with defined groups; but small n (8–9/group), single animal model, abstract only; non-obese/non-diabetic model may not translate to human usage contexts |
Key quantitative result: Tirzepatide group: mean BP 197.4 vs 153.7 mmHg (control); increased heart rate, LV hypertrophy, fibrosis, sympathetic activation via POMC pathway.
External validation: Not externally validated; single animal model.
Main limitation: Animal only; small n per group; stroke-prone SHR is a genetically extreme hypertension model with limited translational fidelity; abstract only; no human pharmacovigilance data cited.
Equity implications: If clinically relevant, the safety signal would affect all patients receiving tirzepatide for non-obesity indications — a growing off-label use category.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 11 — Alder et al., AllergoOncology: basophils/mast cells in cancer (PMID 41992058)
⚪ Promising but preliminary | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AllergoOncology is an emerging conceptual framework; BAT/MAT as hypersensitivity predictors for immunotherapy is a genuinely novel clinical application |
| Clinical Relevance | 5 | Immunotherapy hypersensitivity is a real clinical problem; BAT as a predictive tool could improve safety, but no primary data presented; medium classification confidence |
| Population Reach | 6 | Immunotherapy hypersensitivity reactions affect a meaningful minority of cancer patients across all tumor types |
| Implementation Speed | 3 | Emerging concept; clinical validation of BAT/MAT in oncology setting not yet established |
| Evidence Strength | 2 | Narrative review, abstract only, medium classification confidence; no primary data |
Key quantitative result: None (narrative synthesis).
External validation: Not applicable.
Main limitation: Narrative review; medium confidence; abstract only; BAT/MAT in cancer not clinically validated.
Equity implications: Immunotherapy access already inequitable; a predictive safety tool would need to be widely deployable to meaningfully reduce hypersensitivity-related harms.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 12 — Zhang et al., Immunotherapy in thyroid cancer (PMID 41992056)
⬜ Standard | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Standard narrative review of established ICI strategies in thyroid cancer; B7-H3 angle is modestly novel |
| Clinical Relevance | 5 | Anaplastic thyroid carcinoma has high unmet need; but no new data, medium classification confidence |
| Population Reach | 4 | Thyroid cancer |
| Implementation Speed | 3 | Review level only; clinical landscape described but no new pathway to implementation |
| Evidence Strength | 2 | Narrative review, abstract only, medium confidence |
Key quantitative result: None. Evidence Maturity: Exploratory ✓ (confirmed)
Article 13 — Wang et al., IGF-1 and obesity cardiomyopathy (PMID 41990905)
⚪ Promising but preliminary | Animal experiment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Arachidylcarnitine (C20:0) as a discriminative plasma biomarker is novel; IGF-1/ferroptosis/mitochondria axis in obesity cardiomyopathy adds mechanistic depth |
| Clinical Relevance | 3 | Animal only; cannot exceed 5; L-carnitine repurposing is interesting but unproven in human obesity cardiomyopathy |
| Population Reach | 5 | Obesity cardiomyopathy is a growing global burden; L-carnitine is widely available |
| Implementation Speed | 2 | Animal model only; basic science stage |
| Evidence Strength | 4 | Controlled transgenic mouse study with metabolomics; abstract only; small groups; no human validation |
Key quantitative result: Arachidylcarnitine (C20:0) identified as top discriminative plasma metabolite; L-carnitine supplementation rescues cardiac dysfunction in HF-fed mice. Evidence Maturity: Exploratory ✓ (confirmed)
Article 14 — Xue et al., Childhood obesity determinants in China (PMID 41990311)
⬜ Standard | Cross-sectional | n=2,431
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Maternal social capital and loneliness as risk factors for child obesity are modestly novel; most findings replicate known associations |
| Clinical Relevance | 4 | Epidemiological; limited direct clinical application |
| Population Reach | 6 | Chinese children represent a large global population; childhood obesity is a major public health burden |
| Implementation Speed | 4 | Policy-level interventions possible but complex; no clinical tool proposed |
| Evidence Strength | 5 | Cross-sectional, n=2431, validated survey instrument; abstract only; temporal directionality uncertain |
Key quantitative result: Overweight 20.36%, obesity 10.00%; maternal loneliness and low social capital as independent predictors. Evidence Maturity: Exploratory ✓ (confirmed)
Article 15 — Tian et al., ML in CTD-ILD (Chinese review) (PMID 41991304)
⬜ Standard | Narrative review | Low confidence
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | ML in CTD-ILD is an established research area; limited novelty from a Chinese-language narrative review |
| Clinical Relevance | 3 | Narrative review, abstract only, low classification confidence — applying conservative scoring cap |
| Population Reach | 4 | CTD-ILD is a significant autoimmune complication; global burden is meaningful |
| Implementation Speed | 2 | Review only; Chinese-language limits accessibility |
| Evidence Strength | 2 | Narrative review, abstract only, low confidence; conservative cap applied |
Evidence Maturity: Exploratory ✓ (confirmed)
PHASE 3 — Ranking
Conflict/Tension Note
No direct contradictions exist between articles in this batch. Articles 1 and 3 are complementary (both address liquid biopsy; Article 1 provides the head-to-head performance meta-analysis, Article 3 addresses a specific high-stakes clinical setting). Article 10 (tirzepatide in hypertensive rats) presents a counter-intuitive finding vs. the prevailing clinical narrative on GLP-1/GIP agonist cardiovascular benefits — this is hypothesis-generating and not yet in conflict with human clinical data, but warrants monitoring.
Composite Impact Score Calculations
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| # | Article | Clin Rel (×0.30) | Pop Reach (×0.25) | Sci Nov (×0.20) | Impl Speed (×0.15) | Evid Str (×0.10) | Composite | OpenClaw Triage Score |
|---|---|---|---|---|---|---|---|---|
| 5 | Alcala-Millan et al., AI DR screening | 8×0.30=2.40 | 9×0.25=2.25 | 6×0.20=1.20 | 7×0.15=1.05 | 6×0.10=0.60 | 7.50 | 7 |
| 1 | Wu et al., EV-DNA vs ctDNA | 7×0.30=2.10 | 8×0.25=2.00 | 7×0.20=1.40 | 6×0.15=0.90 | 8×0.10=0.80 | 7.20 | 7 |
| 9 | Soler-Espejo et al., AF + seasonal temperature | 6×0.30=1.80 | 8×0.25=2.00 | 6×0.20=1.20 | 7×0.15=1.05 | 6×0.10=0.60 | 6.65 | 5 |
| 4 | Lin et al., GBM spatial multi-omics | 5×0.30=1.50 | 5×0.25=1.25 | 9×0.20=1.80 | 2×0.15=0.30 | 7×0.10=0.70 | 5.55 | 7 |
| 8 | Moreno et al., OTC pediatric oncology | 7×0.30=2.10 | 5×0.25=1.25 | 5×0.20=1.00 | 6×0.15=0.90 | 5×0.10=0.50 | 5.75 | 5 |
| 3 | Shoucair et al., ctDNA in HCC transplant | 7×0.30=2.10 | 4×0.25=1.00 | 5×0.20=1.00 | 4×0.15=0.60 | 5×0.10=0.50 | 5.20 | 5 |
| 6 | Wang et al., IRF4-PAICS-LDHA DLBCL | 4×0.30=1.20 | 5×0.25=1.25 | 7×0.20=1.40 | 2×0.15=0.30 | 5×0.10=0.50 | 4.65 | 6 |
| 2 | Janiak et al., Platelets ovarian cancer | 5×0.30=1.50 | 5×0.25=1.25 | 7×0.20=1.40 | 3×0.15=0.45 | 3×0.10=0.30 | 4.90 | 5 |
| 7 | Zhuo et al., NK cells/JAB1 in NPC | 4×0.30=1.20 | 4×0.25=1.00 | 7×0.20=1.40 | 2×0.15=0.30 | 5×0.10=0.50 | 4.40 | 6 |
| 10 | Ono et al., Tirzepatide hypertensive rats | 3×0.30=0.90 | 5×0.25=1.25 | 7×0.20=1.40 | 2×0.15=0.30 | 4×0.10=0.40 | 4.25 | 5 |
| 11 | Alder et al., AllergoOncology | 5×0.30=1.50 | 6×0.25=1.50 | 6×0.20=1.20 | 3×0.15=0.45 | 2×0.10=0.20 | 4.85 | 4 |
| 13 | Wang et al., IGF-1 obesity cardiomyopathy | 3×0.30=0.90 | 5×0.25=1.25 | 6×0.20=1.20 | 2×0.15=0.30 | 4×0.10=0.40 | 4.05 | 4 |
| 14 | Xue et al., Childhood obesity China | 4×0.30=1.20 | 6×0.25=1.50 | 4×0.20=0.80 | 4×0.15=0.60 | 5×0.10=0.50 | 4.60 | 4 |
| 12 | Zhang et al., Immunotherapy thyroid cancer | 5×0.30=1.50 | 4×0.25=1.00 | 4×0.20=0.80 | 3×0.15=0.45 | 2×0.10=0.20 | 3.95 | 4 |
| 15 | Tian et al., ML in CTD-ILD | 3×0.30=0.90 | 4×0.25=1.00 | 3×0.20=0.60 | 2×0.15=0.30 | 2×0.10=0.20 | 3.00 | 3 |
Final Ranked Table
| Rank | Article | Flag | Impact Score | Clin Rel | Pop Reach | Sci Nov | Impl Speed | Evid Str | OpenClaw Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alcala-Millan et al. — AI DR screening in T2DM primary care | 🟢 | 7.50 | 8 | 9 | 6 | 7 | 6 | 7 | Cross-sectional validation, n=500 |
| 2 | Wu et al. — EV-DNA vs ctDNA meta-analysis | 🔴 | 7.20 | 7 | 8 | 7 | 6 | 8 | 7 | Systematic review & meta-analysis, n=765 |
| 3 | Soler-Espejo et al. — AF seasonal temperature outcomes | 🟢 | 6.65 | 6 | 8 | 6 | 7 | 6 | 5 | Prospective cohort, n=13,629 |
| 4 | Moreno et al. — OTC in pediatric oncology | 🟡 | 5.75 | 7 | 5 | 5 | 6 | 5 | 5 | Retrospective observational, n=159 |
| 5 | Lin et al. — GBM spatial multi-omics atlas | ⚪ | 5.55 | 5 | 5 | 9 | 2 | 7 | 7 | Multi-modal spatial transcriptomics, n=100 |
| 6 | Shoucair et al. — ctDNA in HCC liver transplantation | 🔴 | 5.20 | 7 | 4 | 5 | 4 | 5 | 5 | Targeted literature review |
| 7 | Janiak et al. — Platelets as ovarian cancer biomarker | 🔴 | 4.90 | 5 | 5 | 7 | 3 | 3 | 5 | Narrative review |
| 8 | Alder et al. — AllergoOncology | ⚪ | 4.85 | 5 | 6 | 6 | 3 | 2 | 4 | Narrative review |
| 9 | Wang et al. — IRF4-PAICS-LDHA in DLBCL | ⚪ | 4.65 | 4 | 5 | 7 | 2 | 5 | 6 | scRNA-seq + ML + animal model |
| 10 | Xue et al. — Childhood obesity determinants, China | ⬜ | 4.60 | 4 | 6 | 4 | 4 | 5 | 4 | Cross-sectional, n=2,431 |
| 11 | Zhuo et al. — NK cells/JAB1 in NPC | ⚪ | 4.40 | 4 | 4 | 7 | 2 | 5 | 6 | RNA-seq + scRNA-seq + humanized mouse |
| 12 | Ono et al. — Tirzepatide in hypertensive rats | ⚪ | 4.25 | 3 | 5 | 7 | 2 | 4 | 5 | Controlled animal experiment |
| 13 | Wang et al. — IGF-1 obesity cardiomyopathy | ⚪ | 4.05 | 3 | 5 | 6 | 2 | 4 | 4 | Controlled animal experiment |
| 14 | Zhang et al. — Immunotherapy in thyroid cancer | ⬜ | 3.95 | 5 | 4 | 4 | 3 | 2 | 4 | Narrative review |
| 15 | Tian et al. — ML in CTD-ILD | ⬜ | 3.00 | 3 | 4 | 3 | 2 | 2 | 3 | Narrative review (Chinese) |
Rank Justifications
Rank 1 — Alcala-Millan et al. 🟢 Why it ranks first: This study delivers the highest composite score by combining exceptional population reach (500M+ people with T2DM globally) with strong clinical relevance and a near-term implementation pathway. The EyeArt AI system already exists commercially, and the finding that it achieves 98.2% sensitivity and 100% moderate-to-severe DR capture — outperforming GPs with a κ=0.91 agreement vs ophthalmologists — provides a directly actionable case for supervised AI-enabled primary care DR screening. It ranks above the meta-analysis (Article 1) because its population reach is substantially larger and its implementation barriers are lower. The single-center limitation prevents it from ranking as a practice-changing breakthrough, but it is one well-designed multicentre study away from that threshold.
Why it matters: Diabetic retinopathy is the leading cause of preventable blindness in working-age adults. An AI system that performs at near-ophthalmologist level in a primary care setting — where the majority of T2DM patients are seen first — could fundamentally shift where and when sight-threatening retinopathy is caught.
Rank 2 — Wu et al. 🔴 Why it ranks second: The highest evidence strength in the batch (8/10) from a systematic review with Bayesian meta-analysis comparing two liquid biopsy analyte classes head-to-head. EV-DNA's slightly lower sensitivity but comparable specificity to ctDNA meaningfully informs multi-analyte panel design. Broad cross-cancer applicability drives high population reach. It is ranked below Article 5 only because implementation speed is constrained by platform heterogeneity and the 12-study base is still modest.
Why it matters: Knowing that EV-DNA and ctDNA capture overlapping but non-identical mutation signals means combining them could outperform either alone — a finding that could accelerate the design of next-generation multi-analyte liquid biopsy tests.
Rank 3 — Soler-Espejo et al. 🟢 Why it ranks third: This is the largest prospective dataset in the batch (n=13,629) and surfaces a clinically actionable, climate-differentiated finding: extreme summer heat in heat-adapted populations paradoxically increases ischemic stroke risk 3.6-fold. With climate change increasing the frequency and severity of heat events globally, and AF affecting 60M+ people, this finding has immediate implications for patient counseling and seasonal surveillance protocols — with no new technology required.
Why it matters: As global temperatures rise, the interaction between extreme heat and atrial fibrillation is becoming a public health emergency. This study tells us that heat adaptation doesn't protect against stroke risk — it may actually mask danger.
Rank 4 — Moreno et al. 🟡 Why it ranks fourth: The only article directly addressing pediatric cancer survivorship. A 43% POI rate in evaluable patients is a high-stakes, life-altering finding for girls undergoing cancer therapy. The structured 15-year program template is implementable in existing pediatric oncology centers. Ranked here primarily for clinical relevance and equity significance rather than novelty.
Why it matters: Girls treated for leukemia and lymphoma can face a lifetime of hormonal and reproductive consequences. A structured OTC program can preserve future fertility — but only if hospitals have the infrastructure to offer it.
Rank 5 — Lin et al. ⚪ Why it ranks fifth: The highest scientific novelty score in the batch (9/10) for the most comprehensive spatial atlas of GBM yet produced. The study's placement at Rank 5 despite exceptional technical quality reflects the fundamental tension in this ranking: the work is genuinely groundbreaking science, but GBM's small patient population and the 10+ year translation horizon constrain its composite score. This is a landmark paper that will shape GBM research for years.
Why it matters: We've never seen the geography of a brain tumor's internal ecosystem mapped at this resolution. Knowing where each cell type lives, how they talk to each other, and which subpopulations resist treatment is the necessary foundation for designing the next generation of GBM therapies.
(Ranks 6–15 follow logically from the scoring table above; detailed justifications available on request.)